<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36674643</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>06</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Gene Therapy in ALS and SMA: Advances, Challenges and Perspectives.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1130</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24021130</ELocationID><Abstract><AbstractText>Gene therapy is defined as the administration of genetic material to modify, manipulate gene expression or alter the properties of living cells for therapeutic purposes. Recent advances and improvements in this field have led to many breakthroughs in the treatment of various diseases. As a result, there has been an increasing interest in the use of these therapies to treat motor neuron diseases (MNDs), for which many potential molecular targets have been discovered. MNDs are neurodegenerative disorders that, in their most severe forms, can lead to respiratory failure and death, for instance, spinal muscular atrophy (SMA) or amyotrophic lateral sclerosis (ALS). Despite the fact that SMA has been known for many years, it is still one of the most common genetic diseases causing infant mortality. The introduction of drugs based on ASOs-nusinersen; small molecules-risdiplam; and replacement therapy (GRT)-Zolgensma has shown a significant improvement in both event-free survival and the quality of life of patients after using these therapies in the available trial results. Although there is still no drug that would effectively alleviate the course of the disease in ALS, the experience gained from SMA gene therapy gives hope for a positive outcome of the efforts to produce an effective and safe drug. The aim of this review is to present current progress and prospects for the use of gene therapy in the treatment of both SMA and ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lejman</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Student Scientific Society, Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panuciak</LastName><ForeName>Kinga</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-9014-5171</Identifier><AffiliationInfo><Affiliation>Student Scientific Society, Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nowicka</LastName><ForeName>Emilia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Student Scientific Society, Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mastalerczyk</LastName><ForeName>Angelika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Student Scientific Society, Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wojciechowska</LastName><ForeName>Katarzyna</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lejman</LastName><ForeName>Monika</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8760-0775</Identifier><AffiliationInfo><Affiliation>Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009134" MajorTopicYN="Y">Muscular Atrophy, Spinal</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">SMA</Keyword><Keyword MajorTopicYN="N">gene therapy</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>21</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36674643</ArticleId><ArticleId IdType="pmc">PMC9860634</ArticleId><ArticleId IdType="doi">10.3390/ijms24021130</ArticleId><ArticleId IdType="pii">ijms24021130</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tosolini A.P., Sleigh J.N. Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis. Front. Mol. Neurosci. 2017;10:405. doi: 10.3389/fnmol.2017.00405.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00405</ArticleId><ArticleId IdType="pmc">PMC5725447</ArticleId><ArticleId IdType="pubmed">29270111</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakharova M. Modern Approaches in Gene Therapy of Motor Neuron Diseases. Med. Res. Rev. 2021;41:2634&#x2013;2655. doi: 10.1002/med.21705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21705</ArticleId><ArticleId IdType="pubmed">32638429</ArticleId></ArticleIdList></Reference><Reference><Citation>Geary R.S., Norris D., Yu R., Bennett C.F. Pharmacokinetics, Biodistribution and Cell Uptake of Antisense Oligonucleotides. Adv. Drug Deliv. Rev. 2015;87:46&#x2013;51. doi: 10.1016/j.addr.2015.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2015.01.008</ArticleId><ArticleId IdType="pubmed">25666165</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardone V., Zhou H., Muntoni F., Ferlini A., Falzarano M.S. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease. Molecules. 2017;22:563. doi: 10.3390/molecules22040563.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules22040563</ArticleId><ArticleId IdType="pmc">PMC6154734</ArticleId><ArticleId IdType="pubmed">28379182</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi X., Gatti P., Papoian T. Safety of Antisense Oligonucleotide and SiRNA-Based Therapeutics. Drug Discov. Today. 2017;22:823&#x2013;833. doi: 10.1016/j.drudis.2017.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2017.01.013</ArticleId><ArticleId IdType="pubmed">28159625</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W., Hu Y., Ju D. Gene Therapy for Neurodegenerative Disorders: Advances, Insights and Prospects. Acta Pharm. Sin. B. 2020;10:1347&#x2013;1359. doi: 10.1016/j.apsb.2020.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2020.01.015</ArticleId><ArticleId IdType="pmc">PMC7488363</ArticleId><ArticleId IdType="pubmed">32963936</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu Y., Liu Y., Noor A., Tran J., Li R. Characteristics and Advantages of Adeno-Associated Virus Vector-Mediated Gene Therapy for Neurodegenerative Diseases. Neural Regen. Res. 2019;14:931. doi: 10.4103/1673-5374.250570.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.250570</ArticleId><ArticleId IdType="pmc">PMC6404499</ArticleId><ArticleId IdType="pubmed">30761996</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolb S.J., Kissel J.T. Spinal Muscular Atrophy. Neurol. Clin. 2015;33:831&#x2013;846. doi: 10.1016/j.ncl.2015.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.004</ArticleId><ArticleId IdType="pmc">PMC4628728</ArticleId><ArticleId IdType="pubmed">26515624</ArticleId></ArticleIdList></Reference><Reference><Citation>Burghes A.H.M., Beattie C.E. Spinal Muscular Atrophy: Why Do Low Levels of Survival Motor Neuron Protein Make Motor Neurons Sick? Nat. Rev. Neurosci. 2009;10:597&#x2013;609. doi: 10.1038/nrn2670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2670</ArticleId><ArticleId IdType="pmc">PMC2853768</ArticleId><ArticleId IdType="pubmed">19584893</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossoll W., Bassell G.J. Spinal Muscular Atrophy and a Model for Survival of Motor Neuron Protein Function in Axonal Ribonucleoprotein Complexes. Results Probl. Cell Differ. 2009;48:289&#x2013;326. doi: 10.1007/400_2009_4/cover.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/400_2009_4/cover</ArticleId><ArticleId IdType="pmc">PMC3718852</ArticleId><ArticleId IdType="pubmed">19343312</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderton R.S., Meloni B.P., Mastaglia F.L., Boulos S. Spinal Muscular Atrophy and the Antiapoptotic Role of Survival of Motor Neuron (SMN) Protein. Mol. Neurobiol. 2013;47:821&#x2013;832. doi: 10.1007/s12035-013-8399-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8399-5</ArticleId><ArticleId IdType="pubmed">23315303</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#x119;drzejowska M. Rdzeniowy Zanik Mi&#x119;&#x15b;ni&#x2014;Deficyt Bia&#x142;ka SMN [Spinal Muscular Atrophy: SMN Protein Deficiency] Neurol. Neurochir. Pol. 2001;35:289&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">11599226</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensel N., Brickwedde H., Tsaknakis K., Grages A., Braunschweig L., L&#xfc;ders K.A., Lorenz H.M., Lippross S., Walter L.M., Tavassol F., et al. Altered Bone Development with Impaired Cartilage Formation Precedes Neuromuscular Symptoms in Spinal Muscular Atrophy. Hum. Mol. Genet. 2020;29:2662&#x2013;2673. doi: 10.1093/hmg/ddaa145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddaa145</ArticleId><ArticleId IdType="pubmed">32644125</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#x119;drzejowska M., Milewski M., Zimowski J., Borkowska J., Kostera-Pruszczyk A., Sielska D., Jurek M., Hausmanowa-Petrusewicz I. Phenotype Modifiers of Spinal Muscular Atrophy: The Number of SMN2 Gene Copies, Deletion in the NAIP Gene and Probably Gender Influence the Course of the Disease. Acta Biochim. Pol. 2009;56:103&#x2013;108. doi: 10.18388/abp.2009_2521.</Citation><ArticleIdList><ArticleId IdType="doi">10.18388/abp.2009_2521</ArticleId><ArticleId IdType="pubmed">19287802</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T.H. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand? Int. J. Mol. Sci. 2020;21:3297. doi: 10.3390/ijms21093297.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21093297</ArticleId><ArticleId IdType="pmc">PMC7246502</ArticleId><ArticleId IdType="pubmed">32392694</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R.N., Singh N.N. Mechanism of Splicing Regulation of Spinal Muscular Atrophy Genes. Adv. Neurobiol. 2018;20:31&#x2013;61. doi: 10.1007/978-3-319-89689-2_2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-89689-2_2</ArticleId><ArticleId IdType="pmc">PMC6026014</ArticleId><ArticleId IdType="pubmed">29916015</ArticleId></ArticleIdList></Reference><Reference><Citation>Lejman J., Zieli&#x144;ski G., Gawda P., Lejman M. Alternative Splicing Role in New Therapies of Spinal Muscular Atrophy. Genes. 2021;12:1346. doi: 10.3390/genes12091346.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes12091346</ArticleId><ArticleId IdType="pmc">PMC8468182</ArticleId><ArticleId IdType="pubmed">34573328</ArticleId></ArticleIdList></Reference><Reference><Citation>Somers E., Lees R.D., Hoban K., Sleigh J.N., Zhou H., Muntoni F., Talbot K., Gillingwater T.H., Parson S.H. Vascular Defects and Spinal Cord Hypoxia in Spinal Muscular Atrophy. Ann. Neurol. 2016;79:217&#x2013;230. doi: 10.1002/ana.24549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24549</ArticleId><ArticleId IdType="pubmed">26506088</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedrotti S., Bielli P., Paronetto M.P., Ciccosanti F., Fimia G.M., Stamm S., Manley J.L., Sette C. The Splicing Regulator Sam68 Binds to a Novel Exonic Splicing Silencer and Functions in SMN2 Alternative Splicing in Spinal Muscular Atrophy. EMBO J. 2010;29:1235&#x2013;1247. doi: 10.1038/emboj.2010.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2010.19</ArticleId><ArticleId IdType="pmc">PMC2857462</ArticleId><ArticleId IdType="pubmed">20186123</ArticleId></ArticleIdList></Reference><Reference><Citation>Wee C.D., Havens M.A., Jodelka F.M., Hastings M.L. Targeting SR Proteins Improves SMN Expression in Spinal Muscular Atrophy Cells. PLoS ONE. 2014;9:e115205. doi: 10.1371/journal.pone.0115205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0115205</ArticleId><ArticleId IdType="pmc">PMC4266657</ArticleId><ArticleId IdType="pubmed">25506695</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y.C., Chang J.G., Liu T.Y., Jong Y.J., Cheng W.L., Yuo C.Y. Securinine Enhances SMN2 Exon 7 Inclusion in Spinal Muscular Atrophy Cells. Biomed. Pharmacother. 2017;88:708&#x2013;714. doi: 10.1016/j.biopha.2017.01.104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2017.01.104</ArticleId><ArticleId IdType="pubmed">28152480</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Lopez A., Tessaro F., Jonker H.R.A., Wacker A., Richter C., Comte A., Berntenis N., Schmucki R., Hatje K., Petermann O., et al. Targeting RNA Structure in SMN2 Reverses Spinal Muscular Atrophy Molecular Phenotypes. Nat. Commun. 2018;9:2032. doi: 10.1038/s41467-018-04110-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-04110-1</ArticleId><ArticleId IdType="pmc">PMC5966403</ArticleId><ArticleId IdType="pubmed">29795225</ArticleId></ArticleIdList></Reference><Reference><Citation>Claborn M.K., Stevens D.L., Walker C.K., Gildon B.L. Nusinersen: A Treatment for Spinal Muscular Atrophy. Ann. Pharm. 2019;53:61&#x2013;69. doi: 10.1177/1060028018789956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1060028018789956</ArticleId><ArticleId IdType="pubmed">30008228</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuri E., Lucibello S., Perulli M., Coratti G., de Sanctis R., Pera M.C., Pane M., Montes J., de Vivo D.C., Darras B.T., et al. Longitudinal Natural History of Type i Spinal Muscular Atrophy: A Critical Review. Orphanet. J. Rare Dis. 2020;15:84. doi: 10.1186/s13023-020-01356-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-020-01356-1</ArticleId><ArticleId IdType="pmc">PMC7132885</ArticleId><ArticleId IdType="pubmed">32248834</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;rard C., Payan C., Hodgkinson I., Fermanian J. A Motor Function Measure for Neuromuscular Diseases. Construction and Validation Study. Neuromuscul. Disord. 2005;15:463&#x2013;470. doi: 10.1016/j.nmd.2005.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2005.03.004</ArticleId><ArticleId IdType="pubmed">16106528</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsey D., Scoto M., Mayhew A., Main M., Mazzone E.S., Montes J., de Sanctis R., Young S.D., Salazar R., Glanzman A.M., et al. Revised Hammersmith Scale for Spinal Muscular Atrophy: A SMA Specific Clinical Outcome Assessment Tool. PLoS ONE. 2017;12:e0172346. doi: 10.1371/journal.pone.0172346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0172346</ArticleId><ArticleId IdType="pmc">PMC5319655</ArticleId><ArticleId IdType="pubmed">28222119</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederiksen S.B., Holm L.L., Larsen M.R., Doktor T.K., Andersen H.S., Hastings M.L., Hua Y., Krainer A.R., Andresen B.S. Identification of SRSF10 as a Regulator of SMN2 ISS-N1. Hum. Mutat. 2021;42:246&#x2013;260. doi: 10.1002/humu.24149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.24149</ArticleId><ArticleId IdType="pmc">PMC7878440</ArticleId><ArticleId IdType="pubmed">33300159</ArticleId></ArticleIdList></Reference><Reference><Citation>Messina S., Sframeli M. New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges. J. Clin. Med. 2020;9:2222. doi: 10.3390/jcm9072222.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9072222</ArticleId><ArticleId IdType="pmc">PMC7408870</ArticleId><ArticleId IdType="pubmed">32668756</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao V.K., Kapp D., Schroth M. Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease. J. Manag. Care Spec. Pharm. 2018;24:S3&#x2013;S16. doi: 10.18553/jmcp.2018.24.12-a.s3.</Citation><ArticleIdList><ArticleId IdType="doi">10.18553/jmcp.2018.24.12-a.s3</ArticleId><ArticleId IdType="pubmed">30582825</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel R.S., Chiriboga C.A., Vajsar J., Day J.W., Montes J., de Vivo D.C., Yamashita M., Rigo F., Hung G., Schneider E., et al. Treatment of Infantile-Onset Spinal Muscular Atrophy with Nusinersen: A Phase 2, Open-Label, Dose-Escalation Study. Lancet. 2016;388:3017&#x2013;3026. doi: 10.1016/S0140-6736(16)31408-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)31408-8</ArticleId><ArticleId IdType="pubmed">27939059</ArticleId></ArticleIdList></Reference><Reference><Citation>A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants with Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy.  [(accessed on 20 December 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT02386553.</Citation></Reference><Reference><Citation>Finkel R.S., Mercuri E., Darras B.T., Connolly A.M., Kuntz N.L., Kirschner J., Chiriboga C.A., Saito K., Servais L., Tizzano E., et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N. Engl. J. Med. 2017;377:1723&#x2013;1732. doi: 10.1056/NEJMoa1702752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1702752</ArticleId><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzone E.S., Mayhew A., Montes J., Ramsey D., Fanelli L., Young S.D., Salazar R., de Sanctis R., Pasternak A., Glanzman A., et al. Revised Upper Limb Module for Spinal Muscular Atrophy: Development of a New Module. Muscle Nerve. 2017;55:869&#x2013;874. doi: 10.1002/mus.25430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25430</ArticleId><ArticleId IdType="pubmed">27701745</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonanno S., Marcuzzo S., Malacarne C., Giagnorio E., Masson R., Zanin R., Arnoldi M.T., Andreetta F., Simoncini O., Venerando A., et al. Circulating MyomiRs as Potential Biomarkers to Monitor Response to Nusinersen in Pediatric SMA Patients. Biomedicines. 2020;8:21. doi: 10.3390/biomedicines8020021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines8020021</ArticleId><ArticleId IdType="pmc">PMC7168147</ArticleId><ArticleId IdType="pubmed">31991852</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonanno S., Cavalcante P., Salvi E., Giagnorio E., Malacarne C., Cattaneo M., Andreetta F., Venerando A., Pensato V., Gellera C., et al. Identification of a Cytokine Profile in Serum and Cerebrospinal Fluid of Pediatric and Adult Spinal Muscular Atrophy Patients and Its Modulation upon Nusinersen Treatment. Front. Cell. Neurosci. 2022;16:437. doi: 10.3389/fncel.2022.982760.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2022.982760</ArticleId><ArticleId IdType="pmc">PMC9406526</ArticleId><ArticleId IdType="pubmed">36035258</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell J.R., Al-Zaidy S., Shell R., Arnold W.D., Rodino-Klapac L.R., Prior T.W., Lowes L., Alfano L., Berry K., Church K., et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N. Engl. J. Med. 2017;377:1713&#x2013;1722. doi: 10.1056/NEJMoa1706198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1706198</ArticleId><ArticleId IdType="pubmed">29091557</ArticleId></ArticleIdList></Reference><Reference><Citation>Samulski R.J., Muzyczka N. AAV-Mediated Gene Therapy for Research and Therapeutic Purposes. Annu. Rev. Virol. 2014;1:427&#x2013;451. doi: 10.1146/annurev-virology-031413-085355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-virology-031413-085355</ArticleId><ArticleId IdType="pubmed">26958729</ArticleId></ArticleIdList></Reference><Reference><Citation>Blessing D., D&#xe9;glon N. Adeno-Associated Virus and Lentivirus Vectors: A Refined Toolkit for the Central Nervous System. Curr. Opin. Virol. 2016;21:61&#x2013;66. doi: 10.1016/j.coviro.2016.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2016.08.004</ArticleId><ArticleId IdType="pubmed">27559630</ArticleId></ArticleIdList></Reference><Reference><Citation>Lykken E.A., Shyng C., Edwards R.J., Rozenberg A., Gray S.J. Recent Progress and Considerations for AAV Gene Therapies Targeting the Central Nervous System. J. Neurodev. Disord. 2018;10:16. doi: 10.1186/s11689-018-9234-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s11689-018-9234-0</ArticleId><ArticleId IdType="pmc">PMC5960126</ArticleId><ArticleId IdType="pubmed">29776328</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray S.J., Woodard K.T., Samulski R.J. Viral Vectors and Delivery Strategies for CNS Gene Therapy. Ther. Deliv. 2010;1:517&#x2013;534. doi: 10.4155/tde.10.50.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/tde.10.50</ArticleId><ArticleId IdType="pmc">PMC4509525</ArticleId><ArticleId IdType="pubmed">22833965</ArticleId></ArticleIdList></Reference><Reference><Citation>Shevtsova Z., Malik J.M.I., Michel U., B&#xe4;hr M., K&#xfc;gler S. Promoters and Serotypes: Targeting of Adeno-Associated Virus Vectors for Gene Transfer in the Rat Central Nervous System in Vitro and in Vivo. Exp. Physiol. 2005;90:53&#x2013;59. doi: 10.1113/expphysiol.2004.028159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/expphysiol.2004.028159</ArticleId><ArticleId IdType="pubmed">15542619</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara J.H., Stanford M.J., Zhu Y., Tu M., Hauswirth W.W., Bohn M.C., Devries S.H., &#xd6;zdinler P.H. Healthy and Diseased Corticospinal Motor Neurons Are Selectively Transduced upon Direct AAV2-2 Injection into the Motor Cortex. Gene Ther. 2016;23:272&#x2013;282. doi: 10.1038/gt.2015.112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2015.112</ArticleId><ArticleId IdType="pmc">PMC4777664</ArticleId><ArticleId IdType="pubmed">26704722</ArticleId></ArticleIdList></Reference><Reference><Citation>Colella P., Ronzitti G., Mingozzi F. Emerging Issues in AAV-Mediated In Vivo Gene Therapy. Mol. Ther. Methods Clin. Dev. 2018;8:87&#x2013;104. doi: 10.1016/j.omtm.2017.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2017.11.007</ArticleId><ArticleId IdType="pmc">PMC5758940</ArticleId><ArticleId IdType="pubmed">29326962</ArticleId></ArticleIdList></Reference><Reference><Citation>Pena S.A., Iyengar R., Eshraghi R.S., Bencie N., Mittal J., Aljohani A., Mittal R., Eshraghi A.A. Gene Therapy for Neurological Disorders: Challenges and Recent Advancements. J. Drug Target. 2020;28:111&#x2013;128. doi: 10.1080/1061186X.2019.1630415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1061186X.2019.1630415</ArticleId><ArticleId IdType="pubmed">31195838</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahajan R. Onasemnogene Abeparvovec for Spinal Muscular Atrophy: The Costlier Drug Ever. Int. J. Appl. Basic Med. Res. 2019;9:127. doi: 10.4103/ijabmr.IJABMR_190_19.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijabmr.IJABMR_190_19</ArticleId><ArticleId IdType="pmc">PMC6652281</ArticleId><ArticleId IdType="pubmed">31392173</ArticleId></ArticleIdList></Reference><Reference><Citation>Day J.W., Finkel R.S., Chiriboga C.A., Connolly A.M., Crawford T.O., Darras B.T., Iannaccone S.T., Kuntz N.L., Pe&#xf1;a L.D.M., Shieh P.B., et al. Onasemnogene Abeparvovec Gene Therapy for Symptomatic Infantile-Onset Spinal Muscular Atrophy in Patients with Two Copies of SMN2 (STR1VE): An Open-Label, Single-Arm, Multicentre, Phase 3 Trial. Lancet Neurol. 2021;20:284&#x2013;293. doi: 10.1016/S1474-4422(21)00001-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00001-6</ArticleId><ArticleId IdType="pubmed">33743238</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Zaidy S.A., Mendell J.R. From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1. Pediatr. Neurol. 2019;100:3&#x2013;11. doi: 10.1016/j.pediatrneurol.2019.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pediatrneurol.2019.06.007</ArticleId><ArticleId IdType="pubmed">31371124</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer K., Ferraiuolo L., Schmelzer L., Braun L., McGovern V., Likhite S., Michels O., Govoni A., Fitzgerald J., Morales P., et al. Improving Single Injection CSF Delivery of AAV9-Mediated Gene Therapy for SMA: A Dose-Response Study in Mice and Nonhuman Primates. Mol. Ther. 2015;23:477&#x2013;487. doi: 10.1038/mt.2014.210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2014.210</ArticleId><ArticleId IdType="pmc">PMC4351452</ArticleId><ArticleId IdType="pubmed">25358252</ArticleId></ArticleIdList></Reference><Reference><Citation>Friese J., Geitmann S., Holzwarth D., M&#xfc;ller N., Sassen R., Baur U., Adler K., Kirschner J. Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec&#x2014;A Single Centre Experience. J. Neuromuscul. Dis. 2021;8:209&#x2013;216. doi: 10.3233/JND-200593.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JND-200593</ArticleId><ArticleId IdType="pmc">PMC8075402</ArticleId><ArticleId IdType="pubmed">33427694</ArticleId></ArticleIdList></Reference><Reference><Citation>van Alstyne M., Tattoli I., Delestr&#xe9;e N., Recinos Y., Workman E., Shihabuddin L.S., Zhang C., Mentis G.Z., Pellizzoni L. Gain of Toxic Function by Long-Term AAV9-Mediated SMN Overexpression in the Sensorimotor Circuit. Nat. Neurosci. 2021;24:930&#x2013;940. doi: 10.1038/s41593-021-00827-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00827-3</ArticleId><ArticleId IdType="pmc">PMC8254787</ArticleId><ArticleId IdType="pubmed">33795885</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell J.R., Al-Zaidy S.A., Lehman K.J., McColly M., Lowes L.P., Alfano L.N., Reash N.F., Iammarino M.A., Church K.R., Kleyn A., et al. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy. JAMA Neurol. 2021;78:834&#x2013;841. doi: 10.1001/jamaneurol.2021.1272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.1272</ArticleId><ArticleId IdType="pmc">PMC8129901</ArticleId><ArticleId IdType="pubmed">33999158</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhillon S. Risdiplam: First Approval. Drugs. 2020;80:1853&#x2013;1858. doi: 10.1007/s40265-020-01410-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-020-01410-z</ArticleId><ArticleId IdType="pubmed">33044711</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. CDER  Highlights of Prescribing Information: EVRYSDI (Risdisplam)  [(accessed on 24 August 2022)]; Available online:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213535s003s005lbl.pdf.</Citation></Reference><Reference><Citation>Sivaramakrishnan M., McCarthy K.D., Campagne S., Huber S., Meier S., Augustin A., Heckel T., Meistermann H., Hug M.N., Birrer P., et al. Binding to SMN2 Pre-MRNA-Protein Complex Elicits Specificity for Small Molecule Splicing Modifiers. Nat. Commun. 2017;8:1476. doi: 10.1038/s41467-017-01559-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01559-4</ArticleId><ArticleId IdType="pmc">PMC5684323</ArticleId><ArticleId IdType="pubmed">29133793</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA Genentech Inc.  EvrysdiTM (Risdiplam): US Prescribing Information.  [(accessed on 5 January 2023)]; Available online:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213535s003s005lbl.pdf.</Citation></Reference><Reference><Citation>Wang J., Schultz P.G., Johnson K.A. Mechanistic Studies of a Small-Molecule Modulator of SMN2 Splicing. Proc. Natl. Acad. Sci. USA. 2018;115:E4604&#x2013;E4612. doi: 10.1073/pnas.1800260115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1800260115</ArticleId><ArticleId IdType="pmc">PMC5960314</ArticleId><ArticleId IdType="pubmed">29712837</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier A., Weetall M., Heinig K., Bucheli F., Schoenlein K., Alsenz J., Bassett S., Ullah M., Senn C., Ratni H., et al. Risdiplam Distributes and Increases SMN Protein in Both the Central Nervous System and Peripheral Organs. Pharmacol. Res. Perspect. 2018;6:e00447. doi: 10.1002/prp2.447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.447</ArticleId><ArticleId IdType="pmc">PMC6262736</ArticleId><ArticleId IdType="pubmed">30519476</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranello G., Servais L., Day J., Deconinck N., Mercuri E., Klein A., Darras B., Masson R., Kletzl H., Cleary Y., et al. P.353FIREFISH Part 1: 16-Month Safety and Exploratory Outcomes of Risdiplam (RG7916) Treatment in Infants with Type 1 Spinal Muscular Atrophy. Neuromuscul. Disord. 2019;29:S184. doi: 10.1016/j.nmd.2019.06.515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2019.06.515</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolb S.J., Coffey C.S., Yankey J.W., Krosschell K., Arnold W.D., Rutkove S.B., Swoboda K.J., Reyna S.P., Sakonju A., Darras B.T., et al. Natural History of Infantile-Onset Spinal Muscular Atrophy. Ann. Neurol. 2017;82:883&#x2013;891. doi: 10.1002/ana.25101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25101</ArticleId><ArticleId IdType="pmc">PMC5776712</ArticleId><ArticleId IdType="pubmed">29149772</ArticleId></ArticleIdList></Reference><Reference><Citation>Servais L., Baranello G., Masson R., Mazurkiewicz-Be&#x142;dzi&#x144;ska M., Rose K., Vlodavets D., Xiong H., Zanoteli E., El-Khairi M., Fuerst-Recktenwald S., et al. FIREFISH Part 2: Efficacy and Safety of Risdiplam (RG7916) in Infants with Type 1 Spinal Muscular Atrophy (SMA) Eur. Respir. J. 2020;56((Suppl. S64)):117. doi: 10.1183/13993003.congress-2020.1172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.congress-2020.1172</ArticleId></ArticleIdList></Reference><Reference><Citation>PTC Therapeutics Announces 2-Year Data from Part 1 of SUNFISH and New Data from JEWELFISH Trials for Risdiplam in Patients with Spinal Muscular Atrophy|PTC Therapeutics, Inc.  [(accessed on 22 December 2022)].  Available online:  https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-announces-2-year-data-part-1-sunfish-and-new.</Citation></Reference><Reference><Citation>Mercuri E., Barisic N., Boespflug-Tanguy O., Deconinck N., Kostera-Pruszczyk A., Masson R., Mazzone E., Nascimento A., Saito K., Vlodavets D., et al.  SUNFISH Part 2: Efficacy and Safety of Risdiplam (RG7916) in Patients with Type 2 or Non-Ambulant Type 3 Spinal Muscular Atrophy (SMA) (1260)  [(accessed on 24 August 2022)];Neurology. 2020 94((Suppl. S15)) Available online:  https://n.neurology.org/content/94/15_Supplement/1260.</Citation></Reference><Reference><Citation>Chiriboga C.A., Mercuri E., Fischer D., Kraus D., Yeung W.Y., Kletzl H., Gerber M., Cleary Y., Gorni K., Khwaja O. JEWELFISH: Risdiplam (RG7916) Increases SMN Protein in Non-Na&#xef;ve Patients with SMA.  [(accessed on 24 August 2022)].  Available online:  https://medically.roche.com/content/dam/pdmahub/non-restricted/neurology/wms-2018/WMS_2018_JEWELFISH_risdiplam_poster_Chiriboga.pdf.</Citation></Reference><Reference><Citation>Finkel R.S., Al-Muhaizea M., Farrar M.A., Nelson L., Prufer A., Servais L., Wang Y., Zanoteli E., Palfreeman L., El-Khairi M., et al.  RAINBOWFISH: A Study of Risdiplam in Newborns with Presymptomatic Spinal Muscular Atrophy (SMA); Proceedings of the MDA Clinical &amp; Scientific Conference; Dallas, TX, USA. 19&#x2013;22 March 2023;  [(accessed on 22 December 2022)].  Available online:  https://www.mdaconference.org/abstract-library/rainbowfish-a-study-of-risdiplam-in-newborns-with-presymptomatic-spinal-muscular-atrophy-sma/</Citation></Reference><Reference><Citation>Erdos J., Wild C. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data. Eur. J. Paediatr. Neurol. 2022;39:1&#x2013;10. doi: 10.1016/j.ejpn.2022.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpn.2022.04.006</ArticleId><ArticleId IdType="pubmed">35533607</ArticleId></ArticleIdList></Reference><Reference><Citation>Calder A.N., Androphy E.J., Hodgetts K.J. Small Molecules in Development for the Treatment of Spinal Muscular Atrophy. J. Med. Chem. 2016;59:10067&#x2013;10083. doi: 10.1021/acs.jmedchem.6b00670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.6b00670</ArticleId><ArticleId IdType="pmc">PMC5744254</ArticleId><ArticleId IdType="pubmed">27490705</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters T., Deconinck N., Valentin M., Kieloch A., Theil D., de Pommerol J.H.P. 273Serum Neurofilament Light Chain in Type 1 Spinal Muscular Atrophy: 30 Months Data from First Part of a Branaplam Phase II Study. Neuromuscul. Disord. 2019;29:S147. doi: 10.1016/j.nmd.2019.06.387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2019.06.387</ArticleId></ArticleIdList></Reference><Reference><Citation>d&#x2019;Ydewalle C., Ramos D.M., Pyles N.J., Ng S.Y., Gorz M., Pilato C.M., Ling K., Kong L., Ward A.J., Rubin L.L., et al. The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy. Neuron. 2017;93:66&#x2013;79. doi: 10.1016/j.neuron.2016.11.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.11.033</ArticleId><ArticleId IdType="pmc">PMC5223741</ArticleId><ArticleId IdType="pubmed">28017471</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond S.M., Hazell G., Shabanpoor F., Saleh A.F., Bowerman M., Sleigh J.N., Meijboom K.E., Zhou H., Muntoni F., Talbot K., et al. Systemic Peptide-Mediated Oligonucleotide Therapy Improves Long-Term Survival in Spinal Muscular Atrophy. Proc. Natl. Acad. Sci. USA. 2016;113:10962&#x2013;10967. doi: 10.1073/pnas.1605731113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1605731113</ArticleId><ArticleId IdType="pmc">PMC5047168</ArticleId><ArticleId IdType="pubmed">27621445</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Benito L., Schneider S., Rombo R., Ling K.K., Grysko V., Upadhyay A., Kononenko N.L., Rigo F., Bennett C.F., Wirth B. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen Further Ameliorates Spinal Muscular Atrophy in Mice. Am. J. Hum. Genet. 2019;105:221&#x2013;230. doi: 10.1016/j.ajhg.2019.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2019.05.008</ArticleId><ArticleId IdType="pmc">PMC6612520</ArticleId><ArticleId IdType="pubmed">31230718</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann B., Kr&#xf6;ber S., Torres-Benito L., Borgmann A., Peters M., Hosseini Barkooie S.M., Tejero R., Jakubik M., Schreml J., Milbradt J., et al. Plastin 3 Ameliorates Spinal Muscular Atrophy via Delayed Axon Pruning and Improves Neuromuscular Junction Functionality. Hum. Mol. Genet. 2013;22:1328&#x2013;1347. doi: 10.1093/hmg/dds540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds540</ArticleId><ArticleId IdType="pubmed">23263861</ArticleId></ArticleIdList></Reference><Reference><Citation>Oprea G.E., Kr&#xf6;ber S., McWhorter M.L., Rossoll W., M&#xfc;ller S., Krawczak M., Bassell G.J., Beattie C.E., Wirth B. Plastin 3 Is a Protective Modifier of Autosomal Recessive Spinal Muscular Atrophy. Science. 2008;320:524&#x2013;527. doi: 10.1126/science.1155085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1155085</ArticleId><ArticleId IdType="pmc">PMC4908855</ArticleId><ArticleId IdType="pubmed">18440926</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad S., Wang Y., Shaik G.M., Burghes A.H., Gangwani L. The Zinc Finger Protein ZPR1 Is a Potential Modifier of Spinal Muscular Atrophy. Hum. Mol. Genet. 2012;21:2745&#x2013;2758. doi: 10.1093/hmg/dds102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds102</ArticleId><ArticleId IdType="pmc">PMC3363332</ArticleId><ArticleId IdType="pubmed">22422766</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., Kaye W., Raymond J., Wu R., Larson T., Punjani R., Heller D., Cohen J., Peters T., Muravov O., et al. Prevalence of Amyotrophic Lateral Sclerosis&#x2014;United States, 2014. MMWR Morb. Mortal. Wkly. Rep. 2019;67:216&#x2013;218. doi: 10.15585/mmwr.mm6707a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6707a3</ArticleId><ArticleId IdType="pmc">PMC5858037</ArticleId><ArticleId IdType="pubmed">29470458</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B., Boum&#xe9;diene F., Logroscino G., Couratier P., Babron M.C., Leutenegger A.L., Copetti M., Preux P.M., Beghi E. Variation in Worldwide Incidence of Amyotrophic Lateral Sclerosis: A Meta-Analysis. Int. J. Epidemiol. 2017;46:57&#x2013;74. doi: 10.1093/ije/dyw061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyw061</ArticleId><ArticleId IdType="pmc">PMC5407171</ArticleId><ArticleId IdType="pubmed">27185810</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulisz D. Amyotrophic Lateral Sclerosis: Disease State Overview. Am. J. Manag. Care. 2018;24:S320&#x2013;S326.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207670</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal M.K. Riluzole and Edaravone: A Tale of Two Amyotrophic Lateral Sclerosis Drugs. Med. Res. Rev. 2019;39:733&#x2013;748. doi: 10.1002/med.21528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedermeyer S., Murn M., Choi P.J. Respiratory Failure in Amyotrophic Lateral Sclerosis. Chest. 2019;155:401&#x2013;408. doi: 10.1016/j.chest.2018.06.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2018.06.035</ArticleId><ArticleId IdType="pubmed">29990478</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappella M., Ciotti C., Cohen-Tannoudji M., Biferi M.G. Gene Therapy for ALS&#x2014;A Perspective. Int. J. Mol. Sci. 2019;20:4388. doi: 10.3390/ijms20184388.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20184388</ArticleId><ArticleId IdType="pmc">PMC6771059</ArticleId><ArticleId IdType="pubmed">31500113</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. CDER  Highlights of Prescribing Information: RILUTEK.  [(accessed on 24 August 2022)]; Available online:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020599s017lbl.pdf.</Citation></Reference><Reference><Citation>Chen J.J. Overview of Current and Emerging Therapies for Amyotrophic Lateral Sclerosis. Am. J. Manag. Care. 2020;26:S191&#x2013;S197. doi: 10.37765/AJMC.2020.88483.</Citation><ArticleIdList><ArticleId IdType="doi">10.37765/AJMC.2020.88483</ArticleId><ArticleId IdType="pubmed">32840332</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakor K., Naud S., Howard D., Tandan R., Waheed W. Effect of Riluzole on Weight in Short-Term and Long-Term Survivors of Amyotrophic Lateral Sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2021;22:360&#x2013;367. doi: 10.1080/21678421.2021.1874992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1874992</ArticleId><ArticleId IdType="pubmed">33467943</ArticleId></ArticleIdList></Reference><Reference><Citation>Safety Study of Oral Edaravone Administered in Subjects with ALS.  [(accessed on 22 December 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04165824.</Citation></Reference><Reference><Citation>Yoshino H., Kimura A. Investigation of the Therapeutic Effects of Edaravone, a Free Radical Scavenger, on Amyotrophic Lateral Sclerosis (Phase II Study) Amyotroph. Lateral Scler. 2006;7:247&#x2013;251. doi: 10.1080/17482960600881870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600881870</ArticleId><ArticleId IdType="pubmed">17127563</ArticleId></ArticleIdList></Reference><Reference><Citation>Genge A., Pattee G.L., Sobue G., Aoki M., Yoshino H., Couratier P., Lunetta C., Petri S., Selness D., Bidani S., et al. Oral Edaravone Demonstrated a Favorable Safety Profile in Patients with Amyotrophic Lateral Sclerosis after 48&#x2009;Weeks of Treatment. Muscle Nerve. :2022. doi: 10.1002/mus.27768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27768</ArticleId><ArticleId IdType="pubmed">36504406</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M., Kim J.R., van Bruggen R., Park J. RNA-Binding Proteins in Amyotrophic Lateral Sclerosis. Moleucles Cells. 2018;41:818&#x2013;829. doi: 10.14348/MOLCELLS.2018.0243.</Citation><ArticleIdList><ArticleId IdType="doi">10.14348/MOLCELLS.2018.0243</ArticleId><ArticleId IdType="pmc">PMC6182225</ArticleId><ArticleId IdType="pubmed">30157547</ArticleId></ArticleIdList></Reference><Reference><Citation>Huai J., Zhang Z. Structural Properties and Interaction Partners of Familial ALS-Associated SOD1 Mutants. Front. Neurol. 2019;10:527. doi: 10.3389/fneur.2019.00527.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00527</ArticleId><ArticleId IdType="pmc">PMC6536575</ArticleId><ArticleId IdType="pubmed">31164862</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L.X., Xu H.F., Wang P.S., Yang X.X., Wu Z.Y., Li H.F. SOD1 Mutation Spectrum and Natural History of ALS Patients in a 15-Year Cohort in Southeastern China. Front. Genet. 2021;12:1891. doi: 10.3389/fgene.2021.746060.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2021.746060</ArticleId><ArticleId IdType="pmc">PMC8551486</ArticleId><ArticleId IdType="pubmed">34721532</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi Y., Homma K., Ichijo H. SOD1 in Neurotoxicity and Its Controversial Roles in SOD1 Mutation-Negative ALS. Adv. Biol. Regul. 2016;60:95&#x2013;104. doi: 10.1016/j.jbior.2015.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbior.2015.10.006</ArticleId><ArticleId IdType="pubmed">26563614</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafinca R., Barbagallo P., Talbot K. The Role of Mitochondrial Dysfunction and ER Stress in TDP-43 and C9ORF72 ALS. Front. Cell Neurosci. 2021;15:97. doi: 10.3389/fncel.2021.653688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.653688</ArticleId><ArticleId IdType="pmc">PMC8047135</ArticleId><ArticleId IdType="pubmed">33867942</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang W., Hu F. Cellular and Physiological Functions of C9ORF72 and Implications for ALS/FTD. J. Neurochem. 2021;157:334&#x2013;350. doi: 10.1111/jnc.15255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15255</ArticleId><ArticleId IdType="pmc">PMC8842544</ArticleId><ArticleId IdType="pubmed">33259633</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.C.A., Flynn H., Adamson J., et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Foggin S., Mesquita-Ribeiro R., Dajas-Bailador F., Layfield R. Biological Significance of MicroRNA Biomarkers in ALS-Innocent Bystanders or Disease Culprits? Front. Neurol. 2019;10:578. doi: 10.3389/fneur.2019.00578.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00578</ArticleId><ArticleId IdType="pmc">PMC6579821</ArticleId><ArticleId IdType="pubmed">31244752</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T.M., Kaspar B.K., Kops G.J., Yamanaka K., Christian L.J., Gage F.H., Cleveland D.W. Virus-Delivered Small RNA Silencing Sustains Strength in Amyotrophic Lateral Sclerosis. Ann. Neurol. 2005;57:773&#x2013;776. doi: 10.1002/ana.20453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20453</ArticleId><ArticleId IdType="pmc">PMC1351126</ArticleId><ArticleId IdType="pubmed">15852369</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralph G.S., Radcliffe P.A., Day D.M., Carthy J.M., Leroux M.A., Lee D.C.P., Wong L.F., Bilsland L.G., Greensmith L., Kingsman S.M., et al. Silencing Mutant SOD1 Using RNAi Protects against Neurodegeneration and Extends Survival in an ALS Model. Nat. Med. 2005;11:429&#x2013;433. doi: 10.1038/nm1205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1205</ArticleId><ArticleId IdType="pubmed">15768029</ArticleId></ArticleIdList></Reference><Reference><Citation>Raoul C., Abbas-Terki T., Bensadoun J.C., Guillot S., Haase G., Szulc J., Henderson C.E., Aebischer P. Lentiviral-Mediated Silencing of SOD1 through RNA Interference Retards Disease Onset and Progression in a Mouse Model of ALS. Nat. Med. 2005;11:423&#x2013;428. doi: 10.1038/nm1207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1207</ArticleId><ArticleId IdType="pubmed">15768028</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust K.D., Salazar D.L., Likhite S., Ferraiuolo L., Ditsworth D., Ilieva H., Meyer K., Schmelzer L., Braun L., Cleveland D.W., et al. Therapeutic AAV9-Mediated Suppression of Mutant SOD1 Slows Disease Progression and Extends Survival in Models of Inherited ALS. Mol. Ther. 2013;21:2148&#x2013;2159. doi: 10.1038/mt.2013.211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2013.211</ArticleId><ArticleId IdType="pmc">PMC3863799</ArticleId><ArticleId IdType="pubmed">24008656</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Yang B., Qiu L., Yang C., Kramer J., Su Q., Guo Y., Brown R.H., Gao G., Xu Z. Widespread Spinal Cord Transduction by Intrathecal Injection of RAAV Delivers Efficacious RNAi Therapy for Amyotrophic Lateral Sclerosis. Hum. Mol. Genet. 2014;23:668&#x2013;681. doi: 10.1093/hmg/ddt454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt454</ArticleId><ArticleId IdType="pmc">PMC3888258</ArticleId><ArticleId IdType="pubmed">24108104</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizvanov A.A., Mukhamedyarov M.A., Palot&#xe1;s A., Islamov R.R. Retrogradely Transported SiRNA Silences Human Mutant SOD1 in Spinal Cord Motor Neurons. Exp. Brain Res. 2009;195:1&#x2013;4. doi: 10.1007/s00221-009-1742-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00221-009-1742-4</ArticleId><ArticleId IdType="pubmed">19259649</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F., Gernoux G., Cardozo B., Metterville J.P., Toro Cabreja G.C., Song L., Su Q., Gao G.P., ElMallah M.K., Brown R.H., et al. Therapeutic RAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates. Hum. Gene Ther. 2016;27:19&#x2013;31. doi: 10.1089/hum.2015.122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2015.122</ArticleId><ArticleId IdType="pmc">PMC4741242</ArticleId><ArticleId IdType="pubmed">26710998</ArticleId></ArticleIdList></Reference><Reference><Citation>Biferi M.G., Cohen-Tannoudji M., Cappelletto A., Giroux B., Roda M., Astord S., Marais T., Bos C., Voit T., Ferry A., et al. A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model. Mol. Ther. 2017;25:2038&#x2013;2052. doi: 10.1016/j.ymthe.2017.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2017.05.017</ArticleId><ArticleId IdType="pmc">PMC5589057</ArticleId><ArticleId IdType="pubmed">28663100</ArticleId></ArticleIdList></Reference><Reference><Citation>Ediriweera G.R., Chen L., Yerbury J.J., Thurecht K.J., Vine K.L. Non-Viral Vector-Mediated Gene Therapy for ALS: Challenges and Future Perspectives. Mol. Pharm. 2021;18:2142&#x2013;2160. doi: 10.1021/acs.molpharmaceut.1c00297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.molpharmaceut.1c00297</ArticleId><ArticleId IdType="pubmed">34010004</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R.A., Miller T.M., Yamanaka K., Monia B.P., Condon T.P., Hung G., Lobsiger C.S., Ward C.M., McAlonis-Downes M., Wei H., et al. Antisense Oligonucleotide Therapy for Neurodegenerative Disease. J. Clin. Investig. 2006;116:2290&#x2013;2296. doi: 10.1172/JCI25424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI25424</ArticleId><ArticleId IdType="pmc">PMC1518790</ArticleId><ArticleId IdType="pubmed">16878173</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T.M., Pestronk A., David W., Rothstein J., Simpson E., Appel S.H., Andres P.L., Mahoney K., Allred P., Alexander K., et al. An Antisense Oligonucleotide against SOD1 Delivered Intrathecally for Patients with SOD1 Familial Amyotrophic Lateral Sclerosis: A Phase 1, Randomised, First-in-Man Study. Lancet Neurol. 2013;12:435&#x2013;442. doi: 10.1016/S1474-4422(13)70061-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70061-9</ArticleId><ArticleId IdType="pmc">PMC3712285</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId></ArticleIdList></Reference><Reference><Citation>Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations.  [(accessed on 22 December 2022)]; Available online:  https://www.clinicaltrials.gov/ct2/show/NCT01041222.</Citation></Reference><Reference><Citation>Miller T., Cudkowicz M., Shaw P.J., Andersen P.M., Atassi N., Bucelli R.C., Genge A., Glass J., Ladha S., Ludolph A.L., et al. Phase 1&#x2013;2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T.M., Cudkowicz M.E., Genge A., Shaw P.J., Sobue G., Bucelli R.C., Chi&#xf2; A., van Damme P., Ludolph A.C., Glass J.D., et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2022;387:1099&#x2013;1110. doi: 10.1056/NEJMoa2204705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204705</ArticleId><ArticleId IdType="pubmed">36129998</ArticleId></ArticleIdList></Reference><Reference><Citation>Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis | Biogen.  [(accessed on 22 December 2022)].  Available online:  https://investors.biogen.com/news-releases/news-release-details/biogen-and-ionis-announce-topline-phase-1-study-results.</Citation></Reference><Reference><Citation>An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults with Inherited Amyotrophic Lateral Sclerosis (ALS)  [(accessed on 22 December 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT02623699.</Citation></Reference><Reference><Citation>Donnelly C.J., Zhang P.W., Pham J.T., Heusler A.R., Mistry N.A., Vidensky S., Daley E.L., Poth E.M., Hoover B., Fines D.M., et al. RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention. Neuron. 2013;80:415&#x2013;428. doi: 10.1016/j.neuron.2013.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.015</ArticleId><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C., Baughn M., Rigo F., Sun S., Liu P., Li H.R., Jiang J., Watt A.T., Chun S., Katz M., et al. Targeted Degradation of Sense and Antisense C9orf72 RNA Foci as Therapy for ALS and Frontotemporal Degeneration. Proc. Natl. Acad. Sci. USA. 2013;110:E4530&#x2013;E4539. doi: 10.1073/pnas.1318835110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1318835110</ArticleId><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D., O&#x2019;Rourke J.G., Meera P., Muhammad A.K.M.G., Grant S., Simpkinson M., Bell S., Carmona S., Ornelas L., Sahabian A., et al. Targeting RNA Foci in IPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion. Sci. Transl. Med. 2013;5:208ra149. doi: 10.1126/scitranslmed.3007529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007529</ArticleId><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J., Zhu Q., Gendron T.F., Saberi S., McAlonis-Downes M., Seelman A., Stauffer J.E., Jafar-nejad P., Drenner K., Schulte D., et al. Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron. 2016;90:535&#x2013;550. doi: 10.1016/j.neuron.2016.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.006</ArticleId><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Hautbergue G.M., Cleary J.D., Guo S., Ranum L.P.W. Therapeutic Strategies for C9orf72 Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Curr. Opin. Neurol. 2021;34:748&#x2013;755. doi: 10.1097/WCO.0000000000000984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000984</ArticleId><ArticleId IdType="pmc">PMC8678157</ArticleId><ArticleId IdType="pubmed">34392299</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Dodart J.C., Tran H., Berkovitch S., Braun M., Byrne M., Durbin A.F., Hu X.S., Iwamoto N., Jang H.G., et al. Variant-Selective Stereopure Oligonucleotides Protect against Pathologies Associated with C9orf72-Repeat Expansion in Preclinical Models. Nat. Commun. 2021;12:847. doi: 10.1038/s41467-021-21112-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21112-8</ArticleId><ArticleId IdType="pmc">PMC7870851</ArticleId><ArticleId IdType="pubmed">33558503</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold C. Tailored Treatment for ALS Poised to Move Ahead. Nat. Med. :2019. doi: 10.1038/d41591-019-00013-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41591-019-00013-w</ArticleId><ArticleId IdType="pubmed">32467611</ArticleId></ArticleIdList></Reference><Reference><Citation>A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants with Fused in Sarcoma Mutations (FUS-ALS)  [(accessed on 22 December 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04768972.</Citation></Reference><Reference><Citation>Codron P., Cassereau J., Vourc&#x2019;h P. InFUSing Antisense Oligonucleotides for Treating ALS. Trends Mol. Med. 2022;28:253&#x2013;254. doi: 10.1016/j.molmed.2022.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2022.02.006</ArticleId><ArticleId IdType="pubmed">35246398</ArticleId></ArticleIdList></Reference><Reference><Citation>Ionis Pipeline: Antisense Drugs for a Broad Range of Diseases.  [(accessed on 22 December 2022)].  Available online:  https://www.ionispharma.com/ionis-innovation/pipeline/</Citation></Reference><Reference><Citation>Becker L.A., Huang B., Bieri G., Ma R., Knowles D.A., Jafar-Nejad P., Messing J., Kim H.J., Soriano A., Auburger G., et al. Therapeutic Reduction of Ataxin-2 Extends Lifespan and Reduces Pathology in TDP-43 Mice. Nature. 2017;544:367&#x2013;371. doi: 10.1038/nature22038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22038</ArticleId><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Duque S., Joussemet B., Riviere C., Marais T., Dubreil L., Douar A.M., Fyfe J., Moullier P., Colle M.A., Barkats M. Intravenous Administration of Self-Complementary AAV9 Enables Transgene Delivery to Adult Motor Neurons. Mol. Ther. 2009;17:1187&#x2013;1196. doi: 10.1038/mt.2009.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2009.71</ArticleId><ArticleId IdType="pmc">PMC2835208</ArticleId><ArticleId IdType="pubmed">19367261</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor D.M., Boulis N.M. Gene Therapy for Neurodegenerative Diseases. Trends Mol. Med. 2015;21:504&#x2013;512. doi: 10.1016/j.molmed.2015.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2015.06.001</ArticleId><ArticleId IdType="pubmed">26122838</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzouz M. Gene Therapy for ALS: Progress and Prospects. Biochim. Et Biophys. Acta (BBA)-Mol. Basis Dis. 2006;1762:1122&#x2013;1127. doi: 10.1016/j.bbadis.2006.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2006.05.003</ArticleId><ArticleId IdType="pubmed">16806843</ArticleId></ArticleIdList></Reference><Reference><Citation>Escors D., Breckpot K. Lentiviral Vectors in Gene Therapy: Their Current Status and Future Potential. Arch. Immunol. Ther. Exp. 2010;58:107&#x2013;119. doi: 10.1007/s00005-010-0063-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00005-010-0063-4</ArticleId><ArticleId IdType="pmc">PMC2837622</ArticleId><ArticleId IdType="pubmed">20143172</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabalza A., Eleftheriadou I., Sgourou A., Liao T.-Y., Patsali P., Lee H., Mazarakis N.D. Enhanced Central Nervous System Transduction with Lentiviral Vectors Pseudotyped with RVG/HIV-1gp41 Chimeric Envelope Glycoproteins. J. Virol. 2014;88:2877&#x2013;2890. doi: 10.1128/JVI.03376-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03376-13</ArticleId><ArticleId IdType="pmc">PMC3958067</ArticleId><ArticleId IdType="pubmed">24371049</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K., Kato S., Kobayashi K. Genetic Manipulation of Specific Neural Circuits by Use of a Viral Vector System. J. Neural. Transm. 2018;125:67&#x2013;75. doi: 10.1007/s00702-016-1674-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-016-1674-7</ArticleId><ArticleId IdType="pubmed">28058503</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury S.R., Hudry E., Maguire C.A., Sena-Esteves M., Breakefield X.O., Grandi P. Viral Vectors for Therapy of Neurologic Diseases. Neuropharmacology. 2017;120:63&#x2013;80. doi: 10.1016/j.neuropharm.2016.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2016.02.013</ArticleId><ArticleId IdType="pmc">PMC5929167</ArticleId><ArticleId IdType="pubmed">26905292</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M., Svendsen C.N. Ex Vivo Gene Therapy Using Human Mesenchymal Stem Cells to Deliver Growth Factors in the Skeletal Muscle of a Familial ALS Rat Model. Methods Mol. Biol. 2016;1382:325&#x2013;336. doi: 10.1007/978-1-4939-3271-9_24/COVER.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-3271-9_24/COVER</ArticleId><ArticleId IdType="pubmed">26611598</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannitti T., Scarrott J.M., Likhite S., Coldicott I.R.P., Lewis K.E., Heath P.R., Higginbottom A., Myszczynska M.A., Milo M., Hautbergue G.M., et al. Translating SOD1 Gene Silencing toward the Clinic: A Highly Efficacious, Off-Target-Free, and Biomarker-Supported Strategy for FALS. Mol. Ther. Nucleic Acids. 2018;12:75&#x2013;88. doi: 10.1016/j.omtn.2018.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2018.04.015</ArticleId><ArticleId IdType="pmc">PMC6023790</ArticleId><ArticleId IdType="pubmed">30195799</ArticleId></ArticleIdList></Reference><Reference><Citation>AveXis, ALS Gene Therapy AVXS-301 to Be Bought by Novartis for $8.7B.  [(accessed on 22 December 2022)].  Available online:  https://alsnewstoday.com/news/avexis-and-als-therapy-avxs-301-to-be-acquired-novartis/</Citation></Reference><Reference><Citation>Statement from Novartis Gene Therapies: OAV301 Program for Familial ALS Caused by SOD1 Mutation&#x2014;Les Turner ALS Foundation.  [(accessed on 22 December 2022)].  Available online:  https://lesturnerals.org/oav301-program-for-familial-als-caused-by-sod1-mutation-statement-from-novartis-gene-therapies/</Citation></Reference><Reference><Citation>Apic Bio Receives FDA Fast Track Designation for APB-102 | Apic Bio.  [(accessed on 22 December 2022)].  Available online:  https://apic-bio.com/apic-bio-receives-fda-fast-track-designation-for-apb-102-for-the-treatment-of-patients-with-sod1-als/</Citation></Reference><Reference><Citation>APB-102 Gene Therapy for SOD1 ALS Wins FDA Fast Track Status.  [(accessed on 22 December 2022)].  Available online:  https://alsnewstoday.com/news/apb-102-gene-therapy-sod1-als-wins-fda-fast-track/</Citation></Reference><Reference><Citation>Mueller C., Berry J.D., McKenna-Yasek D.M., Gernoux G., Owegi M.A., Pothier L.M., Douthwright C.L., Gelevski D., Luppino S.D., Blackwood M., et al. SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. N. Engl. J. Med. 2020;383:151&#x2013;158. doi: 10.1056/NEJMoa2005056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2005056</ArticleId><ArticleId IdType="pubmed">32640133</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyoshi S., Tezuka T., Arimura S., Tomono T., Okada T., Yamanashi Y. DOK7 Gene Therapy Enhances Motor Activity and Life Span in ALS Model Mice. EMBO Mol. Med. 2017;9:880&#x2013;889. doi: 10.15252/emmm.201607298.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201607298</ArticleId><ArticleId IdType="pmc">PMC5494517</ArticleId><ArticleId IdType="pubmed">28490573</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartus R.T., Baumann T.L., Brown L., Kruegel B.R., Ostrove J.M., Herzog C.D. Advancing Neurotrophic Factors as Treatments for Age-Related Neurodegenerative Diseases: Developing and Demonstrating &#x201c;Clinical Proof-of-Concept&#x201d; for AAV-Neurturin (CERE-120) in Parkinson&#x2019;s Disease. Neurobiol. Aging. 2013;34:35&#x2013;61. doi: 10.1016/j.neurobiolaging.2012.07.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.07.018</ArticleId><ArticleId IdType="pubmed">22926166</ArticleId></ArticleIdList></Reference><Reference><Citation>Tovar-y-Romo L.B., Ram&#xed;rez-Jarqu&#xed;n U.N., Lazo-G&#xf3;mez R., Tapia R. Trophic Factors as Modulators of Motor Neuron Physiology and Survival: Implications for ALS Therapy. Front. Cell. Neurosci. 2014;8:61. doi: 10.3389/fncel.2014.00061.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00061</ArticleId><ArticleId IdType="pmc">PMC3937589</ArticleId><ArticleId IdType="pubmed">24616665</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross S.K., Shim B.S., Bartus R.T., Deaver D., McEachin Z., B&#xe9;tourn&#xe9; A., Boulis N.M., Maragakis N.J. Focal and Dose-Dependent Neuroprotection in ALS Mice Following AAV2-Neurturin Delivery. Exp. Neurol. 2020;323:113091. doi: 10.1016/j.expneurol.2019.113091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2019.113091</ArticleId><ArticleId IdType="pubmed">31678350</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H.Q., Hu H.J., Duan W.S., Liu Y.L., Tan G.J., Li Z.Y., Liu Y.K., bin Deng B., Song X.Q., Wang W., et al. Intramuscular Delivery of ScAAV9-HIGF1 Prolongs Survival in the HSOD1G93A ALS Mouse Model via Upregulation of D-Amino Acid Oxidase. Mol. Neurobiol. 2018;55:682&#x2013;695. doi: 10.1007/s12035-016-0335-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0335-z</ArticleId><ArticleId IdType="pubmed">27995572</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai L., Fisher A.L., Huang H., Xie Z. CRISPR-Mediated Genome Editing and Human Diseases. Genes Dis. 2016;3:244&#x2013;251. doi: 10.1016/j.gendis.2016.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gendis.2016.07.003</ArticleId><ArticleId IdType="pmc">PMC6150104</ArticleId><ArticleId IdType="pubmed">30258895</ArticleId></ArticleIdList></Reference><Reference><Citation>Cribbs A.P., Perera S.M.W. Focus: Genome Editing: Science and Bioethics of CRISPR-Cas9 Gene Editing: An Analysis Towards Separating Facts and Fiction. Yale J. Biol. Med. 2017;90:625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5733851</ArticleId><ArticleId IdType="pubmed">29259526</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpe Y., Chen Z., Li X.J. Stem Cell Models and Gene Targeting for Human Motor Neuron Diseases. Pharmaceuticals. 2021;14:565. doi: 10.3390/ph14060565.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14060565</ArticleId><ArticleId IdType="pmc">PMC8231537</ArticleId><ArticleId IdType="pubmed">34204831</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun Y., Ha Y. CRISPR/Cas9-Mediated Gene Correction to Understand ALS. Int. J. Mol. Sci. 2020;21:3801. doi: 10.3390/ijms21113801.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21113801</ArticleId><ArticleId IdType="pmc">PMC7312396</ArticleId><ArticleId IdType="pubmed">32471232</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang H.H.Y., Pannunzio N.R., Adachi N., Lieber M.R. Non-Homologous DNA End Joining and Alternative Pathways to Double-Strand Break Repair. Nat. Rev. Mol. Cell Biol. 2017;18:495&#x2013;506. doi: 10.1038/nrm.2017.48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm.2017.48</ArticleId><ArticleId IdType="pmc">PMC7062608</ArticleId><ArticleId IdType="pubmed">28512351</ArticleId></ArticleIdList></Reference><Reference><Citation>Amado D.A., Davidson B.L. Gene Therapy for ALS: A Review. Mol. Ther. 2021;29:3345&#x2013;3358. doi: 10.1016/j.ymthe.2021.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.008</ArticleId><ArticleId IdType="pmc">PMC8636154</ArticleId><ArticleId IdType="pubmed">33839324</ArticleId></ArticleIdList></Reference><Reference><Citation>Miccio A., Antoniou P., Ciura S., Kabashi E. Novel Genome-Editing-Based Approaches to Treat Motor Neuron Diseases: Promises and Challenges. Mol. Ther. 2022;30:47&#x2013;53. doi: 10.1016/j.ymthe.2021.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.003</ArticleId><ArticleId IdType="pmc">PMC8753272</ArticleId><ArticleId IdType="pubmed">33823304</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakade S., Yamamoto T., Sakuma T. Cas9, Cpf1 and C2c1/2/3&#x2015;What&#x2019;s Next? Bioengineered. 2017;8:265&#x2013;273. doi: 10.1080/21655979.2017.1282018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21655979.2017.1282018</ArticleId><ArticleId IdType="pmc">PMC5470521</ArticleId><ArticleId IdType="pubmed">28140746</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaj T., Ojala D.S., Ekman F.K., Byrne L.C., Limsirichai P., Schaffer D.V. In Vivo Genome Editing Improves Motor Function and Extends Survival in a Mouse Model of ALS. Sci. Adv. 2017;3:eaar3952. doi: 10.1126/sciadv.aar3952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aar3952</ArticleId><ArticleId IdType="pmc">PMC5738228</ArticleId><ArticleId IdType="pubmed">29279867</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan W., Guo M., Yi L., Liu Y., Li Z., Ma Y., Zhang G., Liu Y., Bu H., Song X., et al. The Deletion of Mutant SOD1 via CRISPR/Cas9/SgRNA Prolongs Survival in an Amyotrophic Lateral Sclerosis Mouse Model. Gene Ther. 2019;27:157&#x2013;169. doi: 10.1038/s41434-019-0116-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41434-019-0116-1</ArticleId><ArticleId IdType="pubmed">31819203</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H.X., Zhai H., Shi Y., Liu G., Lowry J., Liu B., Ryan &#xc9;.B., Yan J., Yang Y., Zhang N., et al. Efficacy and Long-Term Safety of CRISPR/Cas9 Genome Editing in the SOD1-Linked Mouse Models of ALS. Commun. Biol. 2021;4:396. doi: 10.1038/s42003-021-01942-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-01942-4</ArticleId><ArticleId IdType="pmc">PMC7994668</ArticleId><ArticleId IdType="pubmed">33767386</ArticleId></ArticleIdList></Reference><Reference><Citation>Pribadi M., Yang Z., Kim T.S., Swartz E.W., Huang A.Y., Chen J.A., Dokuru D., Baek J., Gao F., Fua A.T., et al. CRISPR-Cas9 Targeted Deletion of the C9orf72 Repeat Expansion Mutation Corrects Cellular Phenotypes in Patient-Derived IPS Cells. bioRxiv. 2016:051193. doi: 10.1101/051193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/051193</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R., Yang D., Pribadi M., Kim T.S., Krishnan G., Choi S.Y., Lee S., Coppola G., Gao F.B. Partial Inhibition of the Overactivated Ku80-Dependent DNA Repair Pathway Rescues Neurodegeneration in C9ORF72-ALS/FTD. Proc. Natl. Acad. Sci. USA. 2019;116:9628&#x2013;9633. doi: 10.1073/pnas.1901313116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1901313116</ArticleId><ArticleId IdType="pmc">PMC6511021</ArticleId><ArticleId IdType="pubmed">31019093</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y., Foden J.A., Khayter C., Maeder M.L., Reyon D., Joung J.K., Sander J.D. High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells. Nat. Biotechnol. 2013;31:822&#x2013;826. doi: 10.1038/nbt.2623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2623</ArticleId><ArticleId IdType="pmc">PMC3773023</ArticleId><ArticleId IdType="pubmed">23792628</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y., Cradick T.J., Brown M.T., Deshmukh H., Ranjan P., Sarode N., Wile B.M., Vertino P.M., Stewart F.J., Bao G. CRISPR/Cas9 Systems Have off-Target Activity with Insertions or Deletions between Target DNA and Guide RNA Sequences. Nucleic Acids Res. 2014;42:7473&#x2013;7485. doi: 10.1093/nar/gku402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku402</ArticleId><ArticleId IdType="pmc">PMC4066799</ArticleId><ArticleId IdType="pubmed">24838573</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruminis-Kaszkiel E., Juranek J., Maksymowicz W., Wojtkiewicz J. CRISPR/Cas9 Technology as an Emerging Tool for Targeting Amyotrophic Lateral Sclerosis (ALS) Int. J. Mol. Sci. 2018;19:906. doi: 10.3390/ijms19030906.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19030906</ArticleId><ArticleId IdType="pmc">PMC5877767</ArticleId><ArticleId IdType="pubmed">29562705</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>